Loading stock data…
Sionna Therapeutics, Inc. (SION)
$7.30+0.12 (+1.67%)
Market ClosedLast close Sep 8
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF).
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sionna Therapeutics, Inc. in the Healthcare sector is trading at $7.30 with a market capitalization of $324M. Wall Street consensus targets $15.17 (6 analysts), implying a +107.8% move over the next 12 months. The stock is currently near its 52-week low of $4.01, remaining 80.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +107.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$32.47M↓ | -$29.60M↓ | -$23.61M↑ | -$23.80M↓ | -$21.91M |
| Net Income | -$29.89M↓ | -$26.78M↓ | -$20.44M↓ | -$20.28M↓ | -$18.07M |
Peer Comparison
JNJUNHPFE
Fundamentals
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmemb...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$324.18M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-36.64%
Volume
Today's trading volume
883,782
Recent News
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead
Don't bet against Vertex Pharmaceuticals in cystic fibrosis.
Sionna Therapeutics (SION) Resets After Trial Miss, Is The Discount Now Too Deep?
Sionna Therapeutics (SION) is back in focus after reporting topline results for its cystic fibrosis programs, including a Phase 2a proof of concept miss for SION-719 and supportive Phase 1 data for SION-451 combinations. See our latest analysis for Sionna Therapeutics. The Phase 2a miss for SION-719 triggered a sharp reset in sentiment, with Sionna Therapeutics’ share price down 86.8% over the past week and 84.1% year to date. The 1-year total shareholder return has declined 70.1%, indicating...
Sionna Therapeutics (SION) Is Down 86.8% After Halting SION-719 And Refocusing Its CF Pipeline – Has The Bull Case Changed?
Sionna Therapeutics recently reported that its lead cystic fibrosis candidate SION-719 failed to meet the key activity endpoint in a Phase 2a proof-of-concept trial as an add-on to Trikafta, prompting the company to stop further development in this setting. At the same time, early-stage data supported advancing SION-451 in combination with SION-2222 while management moves to preserve a roughly US$268.30 million cash balance and reassess the pipeline. We will now examine how discontinuing...
Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says
Vertex Pharmaceuticals (VRTX) has multiple potential catalysts coming from its portfolio that provid
Sionna Therapeutics (SION) Stock Still Looks Cheap After The 90% Fall
Sionna Therapeutics stock has fallen sharply in recent sessions, yet the valuation checks suggest it is not a clear bargain even after the sell off. The share price reset sits alongside a low overall value score and a mixed read on what investors are paying for the business today. The stock declined 89.8% over the past week, which signals a major reset in market expectations after recent news. The failure of lead cystic fibrosis candidate SION-719 in a Phase 2a trial can weigh heavily on...